Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

被引：0
|
作者：
Advani, Anjali S.
Jabbour, Elias J.
Stelljes, Matthias
Stock, Wendy
Liedtke, Michaela
Goekbuget, Nicola
O'Brien, Susan M.
White, Jane Liang
Wang, Tao
Laird, A. Douglas
Vandendries, Erik
Kantarjian, Hagop M.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2557
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy.
    DeAngelo, Daniel J.
    Jabbour, Elias
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Gokbuget, Nicola
    Martinelli, Giovanni
    O'Brien, Susan Mary
    Wang, Kongming
    Wang, Tao
    Paccagnella, M. Luisa
    Sleight, Barbara
    Vandendries, Erik
    Advani, Anjali S.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.
    Jabbour, Elias
    Advani, Anjali S.
    Stelljes, Matthias
    Stock, Wendy
    Liedtke, Michaela
    Gokbuget, Nicola
    Martinelli, Giovanni
    O'Brien, Susan Mary
    Wang, Kongming
    Wang, Tao
    Paccagnella, M. Luisa
    Sleight, Barbara
    Vandendries, Erik
    DeAngelo, Daniel J.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Inotuzumab ozogamicin (InO) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) in the global phase 3 randomized controlled ino-vate trial: efficacy and safety by age and prior therapy
    Stelljes, M.
    Kreuzer, K. -A
    Deangelo, D. J.
    Advani, A. S.
    Goekbuget, N.
    Liedtke, M.
    Stock, W.
    Martinelli, G.
    O'Brien, S.
    Wang, K.
    Wang, T.
    Paccagnella, M. L.
    Sleight, B.
    Vandendries, E.
    Jabbour, E. J.
    Kantarjian, H. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 201 - 202
  • [4] Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.
    Cassaday, Ryan Daniel
    DeAngelo, Daniel J.
    Martinelli, Giovanni
    Stock, Wendy
    Stelljes, Matthias
    Gokbuget, Nicola
    Advani, Anjali S.
    O'Brien, Susan Mary
    Liedtke, Michaela
    Merchantx, Akil Abid
    Wang, Tao
    Vandendries, Erik
    Marks, David I.
    Jabbour, Elias
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.
    Jabbour, Elias
    Gokbuget, Nicola
    Advani, Anjali S.
    Stelljes, Matthias
    Stock, Wendy
    Liedtke, Michaela
    Martinelli, Giovanni
    O'Brien, Susan Mary
    Wang, Tao
    Laird, Douglas
    Vandendries, Erik
    Neuhof, Alexander
    DeAngelo, Daniel J.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] INOTUZUMAB OZOGAMICIN FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL: EFFICACY AND SAFETY BY PRIOR THERAPY
    DeAngelo, D. J.
    Jabbour, E. J.
    Stelljes, M.
    Liedtke, M.
    Stock, W.
    Goekbuget, N.
    Martinelli, G.
    O'Brien, S.
    Wang, K.
    Wang, T.
    Paccagnella, M. L.
    Sleight, B.
    Vandendries, E.
    Advani, A. S.
    Kantarjian, H. M.
    HAEMATOLOGICA, 2016, 101 : 184 - 184
  • [7] Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial
    Zhao, Yaqi
    Laird, A. Douglas
    Roberts, Kathryn
    Yafawi, Rolla
    Kantarjian, Hagop
    DeAngelo, Daniel J.
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Gokbuget, Nicola
    O'Brien, Susan
    Jabbour, Elias
    Cassaday, Ryan D.
    Loyd, Melanie R.
    Olsen, Scott
    Neale, Geoffrey
    Liu, Xueli
    Vandendries, Erik
    Mullighan, Charles G.
    Advani, Anjali
    CANCER RESEARCH, 2022, 82 (12)
  • [8] Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%).
    Advani, Anjali S.
    DeAngelo, Daniel J.
    Marks, David I.
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Goekbuget, Nicola
    O'Brien, Susan Mary
    Jabbour, Elias
    Merchant, Akil Abid
    Wang, Tao
    Vandendries, Erik
    Neuhof, Alexander
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study
    Kantarjian, Hagop M.
    DeAngelo, Daniel J.
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Goekbuget, Nicola
    O'Brien, Susan M.
    Jabbour, Elias J.
    Wang, Tao
    White, Jane Liang
    Sleight, Barbara
    Vandendries, Erik
    Advani, Anjali S.
    BLOOD, 2017, 130
  • [10] EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN OLDER PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ENROLLED IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL
    Jabbour, E. J.
    Advani, A. S.
    Stelljes, M.
    Stock, W.
    Liedtke, M.
    Goekbuget, N.
    Martinelli, G.
    O'Brien, S.
    Wang, K.
    Wang, T.
    Paccagnella, M. L.
    Sleight, B.
    Vandendries, E.
    DeAngelo, D. J.
    Kantarjian, H. M.
    HAEMATOLOGICA, 2016, 101 : 32 - 32
12345